P3, N=108, Active, not recruiting, Chengdu New Radiomedicine Technology Co. LTD. | Recruiting --> Active, not recruiting

DOTATOC PET showed no uptake in the pancreatic lesion but revealed high uptake in the primary ASPS in scapula and previously unrecognized metastases in the breast and skull, indicating high somatostatin receptor (SSTR) expression. To our knowledge, this is the first report of DOTATOC uptake in ASPS, which raises the prospect of SSTR-targeted treatment with 177Lu-DOTATATE.

P2, N=62, Completed, Novartis Pharmaceuticals | Active, not recruiting --> Completed

P1, N=48, Recruiting, Novartis Pharmaceuticals | Active, not recruiting --> Recruiting

P2/3, N=30, Recruiting, Telix Pharmaceuticals (Innovations) Pty Limited | Not yet recruiting --> Recruiting

Hybrid PET/MRI improves hepatic lesion characterization and reduces radiation in appropriate patients, while CT/MRI remains indispensable for morphology and complications. Integrating multi-tracer PET with anatomic imaging refines risk stratification, PRRT selection, and longitudinal response assessment.

P1/2, N=25, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jun 2027 --> Mar 2030 | Trial primary completion date: Jun 2026 --> Mar 2029

A 79-year-old woman with suspected choroidal lesion underwent 18F-FDG PET/CT, which revealed a non-FDG-avid right thyroid lobe incidentaloma (4.8 cm in largest dimension) that was cold on 99mTc-thyroid scan, showed intense SSTR expression on 68Ga-DOTATATE PET/CT, and MIBG avidity on 131I-MIBG scan, thereby proving it to be of neural crest origin. Fine needle aspiration biopsy (FNAB) with immunohistochemistry was positive for GATA3 and synaptophysin and negative for CK7, PAX8, TTF1, and calcitonin, establishing the diagnosis of thyroid paraganglioma. Even though rare, the diagnosis of paraganglioma should be considered in SSTR and MIBG-avid thyroid nodules, as seen in this case.

P2, N=10, Recruiting, OHSU Knight Cancer Institute | Not yet recruiting --> Recruiting | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027

P2, N=48, Recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Not yet recruiting --> Recruiting

P1, N=48, Active, not recruiting, Novartis Pharmaceuticals | Recruiting --> Active, not recruiting

[177Lu]Lu-FAPI-46 demonstrated lower therapeutic efficacy, as a monotherapy or in combination with temozolomide, than did [225Ac]Ac-FAPI-46. FAPI-46 demonstrates significant potential as a theranostic agent for glioblastoma in peripheral models. However, its inability to cross the blood-brain barrier in orthotopic models highlights the need for future studies to improve its clinical applicability.